ArticlePharmacology, biochemistry, and behavior2007
Effects of the cannabinoid antagonist SR141716 (rimonabant) and d-amphetamine on palatable food and food pellet intake in non-human primates.
Article in Pharmacology, biochemistry, and behavior, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 31 citations in OpenAlex.
- The Neurobiology of Binge-eating Disorder Compared with Obesity: Implications for Differential Therapeutics.Clinical therapeutics · 2021Review
- Sex differences in the anorexigenic effects of dexfenfluramine and amphetamine in baboons.Experimental and clinical psychopharmacology · 2018Article
- Can We Selectively Reduce Appetite for Energy-Dense Foods? An Overview of Pharmacological Strategies for Modification of Food Preference Behavior.Current neuropharmacology · 2016Review
- The endocannabinoid system: directing eating behavior and macronutrient metabolism.Frontiers in psychology · 2014Review
- Pharmacological modulation of the endocannabinoid signalling alters binge-type eating behaviour in female rats.British journal of pharmacology · 2013Article
- The behavioral pharmacology of anorexigenic drugs in nonhuman primates: 30 years of progress.Behavioural pharmacology · 2012Review
- Article
- Characterization of a novel, brain-penetrating CB1 receptor inverse agonist: metabolic profile in diet-induced obese models and aspects of central activity.Naunyn-Schmiedeberg's archives of pharmacology · 2011Article
- Sex and cannabinoid CB1 genotype differentiate palatable food and cocaine self-administration behaviors in mice.Behavioural pharmacology · 2009Article
- Delta-9-tetrahydrocannabinol enhances food reinforcement in a mouse operant conflict test.Psychopharmacology · 2009Article
- Antagonism of glutamatergic NMDA and mGluR5 receptors decreases consumption of food in baboon model of binge-eating disorder.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology · 2008Article
- Intermittent access to preferred food reduces the reinforcing efficacy of chow in rats.American journal of physiology. Regulatory, integrative and comparative physiology · 2008Article
- A novel procedure for assessing the effects of drugs on satiation in baboons: effects of memantine and dexfenfluramine.Psychopharmacology · 2008Article
- Cannabinoid-1 receptor antagonists reduce caloric intake by decreasing palatable diet selection in a novel dessert protocol in female rats.American journal of physiology. Regulatory, integrative and comparative physiology · 2008Article
- The endocannabinoid system in the baboon (Papio spp.) as a complex framework for developmental pharmacology.Neurotoxicology and teratologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
The purpose of this study was to determine if a cannabinoid CB(1) receptor antagonist would selectively decrease consumption of highly palatable food in non-human primates. The CB(1) receptor antagonist SR141716 (rimonabant; 0.12-1.0 mg/kg, i.m.) and the stimulant anorectic drug d-amphetamine (0.12-1.0 mg/kg, i.m.) were administered to non-food deprived baboons for the purpose of measuring the effect of each drug on consumption of the normal diet, and a large single meal of a high-carbohydrate candy. Four male and four female baboons had access to food 24 h each day, but they had to complete a two phase operant procedure in order to eat. Responding on one lever during a 30-min appetitive phase was required before animals could start a consumption phase, where responding on another lever led to food delivery, i.e., a meal. Three days a week baboons received a jelly sugar-coated candy (Skittles) during the first meal and then pellets were available in subsequent meals. All baboons ate as many individual candies in one meal as they did pellets throughout the entire day. Acute d-amphetamine and, to a lesser extent, SR141716 decreased both candy intake in a single meal and pellet intake in a single meal and over 24 h. d-Amphetamine, but not SR141716, increased latency to the candy meal and the first pellet meal indicating that the two drugs differentially altered feeding topography. Although males ate more food pellets than females, few other sex differences were observed. Thus, although effective in decreasing food intake, there was no evidence of a specific effect of CB(1) receptor antagonism on consumption of a large meal or a palatable food.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.